ZA816809B - Aminoalkylfuran derivative - Google Patents

Aminoalkylfuran derivative

Info

Publication number
ZA816809B
ZA816809B ZA816809A ZA816809A ZA816809B ZA 816809 B ZA816809 B ZA 816809B ZA 816809 A ZA816809 A ZA 816809A ZA 816809 A ZA816809 A ZA 816809A ZA 816809 B ZA816809 B ZA 816809B
Authority
ZA
South Africa
Prior art keywords
aminoalkylfuran
derivative
aminoalkylfuran derivative
Prior art date
Application number
ZA816809A
Other languages
English (en)
Inventor
Derek Leslie Crookes
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA816809(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA816809B publication Critical patent/ZA816809B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
ZA816809A 1980-10-01 1981-10-01 Aminoalkylfuran derivative ZA816809B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8031634 1980-10-01

Publications (1)

Publication Number Publication Date
ZA816809B true ZA816809B (en) 1983-05-25

Family

ID=10516407

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA816809A ZA816809B (en) 1980-10-01 1981-10-01 Aminoalkylfuran derivative

Country Status (29)

Country Link
US (2) US4521431A (xx)
JP (1) JPS5791983A (xx)
KR (1) KR870001431B1 (xx)
AT (1) AT389696B (xx)
AU (1) AU549119B2 (xx)
BE (1) BE890574A (xx)
CA (1) CA1202638A (xx)
CH (1) CH652122A5 (xx)
CZ (1) CZ280885B6 (xx)
DE (1) DE3139134A1 (xx)
DK (2) DK167794B1 (xx)
ES (1) ES505951A0 (xx)
FR (1) FR2491067A1 (xx)
GR (1) GR72499B (xx)
HK (1) HK97985A (xx)
IE (1) IE51604B1 (xx)
IL (1) IL63968A (xx)
IT (1) IT1143237B (xx)
KE (1) KE3549A (xx)
LU (1) LU83661A1 (xx)
MY (1) MY8500747A (xx)
NL (1) NL8104482A (xx)
NZ (1) NZ198522A (xx)
PH (2) PH19489A (xx)
PT (1) PT73744B (xx)
SE (1) SE453500B (xx)
SK (1) SK277922B6 (xx)
ZA (1) ZA816809B (xx)
ZW (1) ZW24481A1 (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR242029A1 (es) * 1983-07-15 1993-02-26 Richter Gedeon Vegyeszet Procedimiento para la preparacion del clorhidrato de 1-(2-(5- dimetilaminometil-2-(furilmetiltio)-etil))-amino-1-metilamino-2-nitroetileno
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
CN1048984C (zh) * 1991-12-20 2000-02-02 多坎化学有限公司 晶形1呋喃硝胺氢氯化物的制备
KR100296810B1 (ko) * 1993-03-12 2001-10-24 로렌스 티. 마이젠헬더 결정성세프티오퍼유리산
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
EP0754182A1 (en) * 1994-04-08 1997-01-22 Brantford Chemicals Inc. Form 1 ranitidine hydrochloride with increased density
ES2164147T3 (es) 1994-04-15 2002-02-16 Upjohn Co Nuevas formas cristalinas de la 2-(5-metanosulfonamido-indolil-2-carbonil)-4-(3-(1-metiletilamino)-2-piperidinil)piperazina.
IN181699B (xx) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
NZ272054A (en) * 1994-05-13 1996-05-28 Ranbaxy Lab Ltd Process for producing form 1 ranitidine hydrochloride
IN181698B (xx) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CA2189007C (en) * 1994-05-18 2004-03-02 Daniel R. Henton Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
ES2122387T3 (es) 1994-06-24 1998-12-16 Ranbaxy Lab Ltd Procedimiento para la preparacion de la forma 1 del clorhidrato de ranitidina.
CA2201735A1 (en) * 1994-11-18 1996-05-30 The Upjohn Company A new physically stable solid form of a fluoroquinolone
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
AU1972097A (en) * 1996-03-25 1997-10-17 Hoechst Marion Roussel, Inc. Process for the preparation of form 1 ranitidine hydrochloride
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
IT1317858B1 (it) 2000-02-29 2003-07-15 Pharmexcel S R L Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
WO2004043920A1 (en) * 2002-11-08 2004-05-27 Dov Pharmaceuticals, Inc. Polymorphs of bicifadine hydrochloride
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) * 2003-07-14 2008-06-10 Applied Ambient Extraction Process Consultants, Llc Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
EP2719384B1 (en) 2005-07-27 2018-08-08 Otsuka America Pharmaceutical, Inc. Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
EP2330101A1 (en) * 2006-10-20 2011-06-08 Scinopharm Singapore Pte, Ltd. Process for making crystalline docetaxel
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
CN103619823B (zh) * 2011-06-30 2016-01-20 东丽株式会社 甘氨酸衍生物的晶体及其药物用途
CN106397374A (zh) * 2015-05-26 2017-02-15 烟台市华文欣欣医药科技有限公司 一种制备治疗胃病的药物盐酸雷尼替丁化合物的方法
CN105030694A (zh) * 2015-08-04 2015-11-11 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) * 2015-08-05 2015-10-14 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE3139134C2 (xx) 1990-04-19
SE453500B (sv) 1988-02-08
DK33792A (da) 1992-03-12
US4521431A (en) 1985-06-04
PT73744A (en) 1981-10-01
FR2491067A1 (fr) 1982-04-02
PH19489A (en) 1986-05-14
ES8301954A1 (es) 1983-01-01
HK97985A (en) 1985-12-13
ES505951A0 (es) 1983-01-01
PT73744B (en) 1983-10-31
CA1202638A (en) 1986-04-01
IT8149407A0 (it) 1981-10-01
CZ280885B6 (cs) 1996-04-17
ATA422281A (de) 1989-06-15
PH21761A (en) 1988-02-18
GR72499B (xx) 1983-11-15
SK403591A3 (en) 1995-08-09
JPH0443070B2 (xx) 1992-07-15
KE3549A (en) 1985-08-16
US4672133A (en) 1987-06-09
DK167923B1 (da) 1994-01-03
IE51604B1 (en) 1987-01-21
CZ403591A3 (en) 1994-01-19
ZW24481A1 (en) 1983-04-27
KR830007070A (ko) 1983-10-14
AU7595581A (en) 1982-04-08
CH652122A5 (fr) 1985-10-31
FR2491067B1 (xx) 1984-09-07
JPS5791983A (en) 1982-06-08
MY8500747A (en) 1985-12-31
IL63968A (en) 1985-10-31
SK277922B6 (en) 1995-08-09
AT389696B (de) 1990-01-10
IE812287L (en) 1982-04-01
LU83661A1 (fr) 1983-06-08
SE8105812L (sv) 1982-04-02
IT1143237B (it) 1986-10-22
BE890574A (fr) 1982-04-01
DK33792D0 (da) 1992-03-12
DK436281A (da) 1982-04-02
DE3139134A1 (de) 1982-05-19
NL8104482A (nl) 1982-05-03
AU549119B2 (en) 1986-01-16
DK167794B1 (da) 1993-12-13
KR870001431B1 (ko) 1987-08-06
NZ198522A (en) 1985-07-12
IL63968A0 (en) 1981-12-31

Similar Documents

Publication Publication Date Title
ZA816809B (en) Aminoalkylfuran derivative
GB2079270B (en) Imidazo-rifamycin derivatives
HK17586A (en) N-arylbenzamide derivatives
JPS5785379A (en) 3-aryl-5-isothiazole derivative
GB2086380B (en) L-argininal derivatives
JPS56150050A (en) Oxitocin derivative
JPS5781476A (en) Isooxazolylbenzamide derivative
GB2083462B (en) 2-thiopenem derivatives
GB2088365B (en) Moranoline derivative
GB2067989B (en) Bis-moranoline derivatives
PH18633A (en) Novel antrancyclinone derivative
GB2075499B (en) Nonaprenylamine derivatives
GB8324990D0 (en) 3-aminopropoxyphenyl derivatives
JPS577467A (en) Novel phenylpropargylamine derivative
GB2088379B (en) 1-phenethylimidazole derivatives
JPS5793949A (en) Alpha-cyanophenoxybenzylamine derivative
GB2085882B (en) Aprosamine derivatives
GB2076815B (en) Aminophenylpyridine derivatives
GB2074165B (en) Nonaprenylamine derivatives
GB2070589B (en) 7a1methoxycephalospin derivatives
GB2076395B (en) Nonaprenylamine derivatives
JPS57118540A (en) Bis-aminomethyl-anthraquinone derivative
GB2073201B (en) Steroid-spiro-oxathiazolidine derivatives
JPS56133270A (en) Substituted phenoxy-aminopropanol derivative
GB2069998B (en) Benzenethiocarbamate derivatives